Drugs for Autosomal Dominant Cerebellar Ataxia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 41)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Nootropic Agents |
|
Phase 4 |
|
|
|
2 |
|
TA 0910 |
|
Phase 4 |
|
|
|
3 |
|
Riluzole |
Approved, Investigational |
Phase 3 |
|
1744-22-5 |
5070 |
Synonyms:
2 Amino 6 trifluoromethoxybenzothiazole
2-Amino-6-trifluoromethoxybenzothiazole
Aventis behring brand OF riluzole
Aventis brand OF riluzole
BHV-0223
Impax brand OF riluzole
Rhone poulenc rorer brand OF riluzole
Rhone-poulenc rorer brand OF riluzole
Rilutek
|
Rilutek®|RP-54274|Tiglutik® (thickened oral suspension)
RILUZOL
RILUZOLE
Riluzole aventis brand
Riluzole impax brand
RILUZOLUM
RP-54274
TEGLUTIK
TIGLUTIK KIT
|
|
4 |
|
Lithium carbonate |
Approved |
Phase 2, Phase 3 |
|
554-13-2 |
|
Synonyms:
CAMCOLIT 250
CAMCOLIT 400
Carbonic acid, dilithium salt
CP-1546761
CP-15467-61
Dilithium carbonate
ESKALITH
ESKALITH CR
LISKONUM
|
LITHANE
Lithii carbonas
LITHIUM CARBONATE
LITHOBID
LITHONATE
LITHOTABS
NSC-16895
PHASAL
|
|
5 |
|
Glutamic acid |
Approved, Nutraceutical |
Phase 3 |
|
56-86-0 |
33032 |
Synonyms:
(+)-Estrone
(1S)-2-[(3-O-b-D-Glucopyranosyl-b-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoate
(1S)-2-[(3-O-b-D-Glucopyranosyl-b-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(1S)-2-[(3-O-beta-D-Glucopyranosyl-beta-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(1S)-2-[(3-O-Β-D-glucopyranosyl-β-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoate
(1S)-2-[(3-O-Β-D-glucopyranosyl-β-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(2R)-2,3-Dihydroxypropanoic acid
(2S)-2-Aminopentanedioate
(2S)-2-Aminopentanedioic acid
(3R,4S,5R)-5-[(1R)-1-Carboxy-2,2-difluoro-1-(phosphonooxy)ethoxy]-4-hydroxy-3-(phosphonooxy)cyclohex-1-ene-1-carboxylate
(R)-2,3-Dihydroxypropanoic acid
(R)-Glycerate
(R)-Glyceric acid
(S)-(+)-Glutamate
(S)-(+)-Glutamic acid
(S)-2-Aminopentanedioate
(S)-2-Aminopentanedioic acid
(S)-Glutamate
(S)-Glutamic acid
1,3,5(10)-Estratrien-3-ol-17-one
1-Amino-2-hydroxyethane
1-Aminopropane-1,3-dicarboxylate
1-Amino-propane-1,3-dicarboxylate
1-Aminopropane-1,3-dicarboxylic acid
1-Amino-propane-1,3-dicarboxylic acid
2 Acetamido 2 deoxy D glucose
2 Acetamido 2 deoxyglucose
2 Aminoethanol
2-Acetamido-2-deoxy-D-glucose
2-Acetamido-2-deoxyglucose
2-Amino-1-ethanol
2-Aminoethan-1-ol
2-Aminoethanol
2-Amino-ethanol
2-Aminoethyl alcohol
2-Aminoglutarate
2-Aminoglutaric acid
2-Aminopentanedioate
2-Aminopentanedioic acid
2-Ethanolamine
2-Hydroxyethanamine
2-Hydroxyethylamine
3a,7a,12a-Trihydroxy-5b-cholan-24-oylglycine
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oylglycine
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid-24-glycine
3alpha,7alpha,12alpha-Trihydroxy-N-(carboxymethyl)-5beta-cholan-24-amide
3-Hydroxy-1,3,5(10)-estratrien-17-one
3-Hydroxy-17-keto-estra-1,3,5-triene
3-Hydroxyestra-1,3,5(10)-trien-17-one
3-Hydroxyestra-1,3,5(10)-triene-17-one
3-Hydroxyoestra-1,3,5(10)-trien-17-one
3Α,7α,12α-trihydroxy-5β-cholan-24-oylglycine
3Α,7α,12α-trihydroxy-5β-cholanic acid-24-glycine
3Α,7α,12α-trihydroxy-N-(carboxymethyl)-5β-cholan-24-amide
a,b-Hydroxypropionate
a,b-Hydroxypropionic acid
a-Aminoglutarate
a-Aminoglutaric acid
Acetylglucosamine
Acide glutamique
Acido glutamico
ácido glutámico
Acidum glutamicum
Aciglut
Aethanolamin
a-Glutamate
a-Glutamic acid
alpha,beta-Hydroxypropionate
alpha,beta-Hydroxypropionic acid
alpha-Aminoglutarate
alpha-Aminoglutaric acid
alpha-Glutamate
alpha-Glutamic acid
Aluminum L glutamate
Aluminum L-glutamate
Aminoethanol
Aminoglutarate
Aminoglutaric acid
b-Aminoethanol
b-Aminoethyl alcohol
beta-Aminoethanol
beta-Aminoethyl alcohol
beta-Ethanolamine
beta-Hydroxyethylamine
b-Ethanolamine
b-Hydroxyethylamine
Cholylglycine
Colamine
D Glutamate
D1,3,5(10)-Estratrien-3-ol-17-one
D-2,3-Dihydroxypropanoic acid
D-GlcNAc
D-Glutamate
|
D-Glycerate
D-Glyceric acid
D-GroA
E
E 620
E620
E-620
Envision conditioner PDD 9020
Estrone, (+-)-isomer
Estrone, (8 alpha)-isomer
Estrone, (9 beta)-isomer
Estrovarin
ETA
Ethylolamine
FEMA NO. 3285
Follicular hormone
Folliculin
Glt
Glu
Glusate
Glut
Glutacid
Glutamate
Glutamate, potassium
GLUTAMIC ACID
Glutamic acid, (D)-isomer
Glutamicol
Glutamidex
Glutaminate
Glutaminic acid
Glutaminol
Glutaton
Glycerate
Glycine cholate
Glycinol
Glycocholate
Glycocholate sodium
Glycocholic acid, sodium salt
Glycoreductodehydrocholic acid
Glycylcholate
Glycylcholic acid
Hauck brand OF estrone
Hea
H-Glycinol
Hyrex brand OF estrone
INS NO.620
INS-620
Kestrone
L Glutamate
L Glutamic acid
L-(+)-Glutamate
L-(+)-Glutamic acid
L-a-Aminoglutarate
L-a-Aminoglutaric acid
L-alpha-Aminoglutarate
L-alpha-Aminoglutaric acid
L-Glu
L-Glu|L-glutamate|poly-L-glutamate
L-GLUTAMATE
L-Glutamate, aluminum
L-GLUTAMIC ACID
L-Glutaminate
L-Glutaminic acid
L-Glutaminsaeure
MEA
Monoaethanolamin
MONOETHANOLAMINE
N Acetyl D glucosamine
N-(Carboxymethyl)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-amide
N-(Carboxymethyl)-3α,7α,12α-trihydroxy-5β-cholan-24-amide
N-[(3a,5b,7a,12a)-3,7,12-Trihydroxy-24-oxocholan-24-yl]glycine
N-[(3alpha,5beta,7alpha,12alpha)-3,7,12-Trihydroxy-24-oxocholan-24-yl]glycine
N-[(3Α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]glycine
N-Acetylchitosamine
N-Acetyl-D-glucosamine
N-Choloylglycine
N-Choloyl-glycine
NSC-143503
Oestrone
Olamine
Potassium glutamate
R-Glycerate
R-Glyceric acid
Unigen
Vortech brand OF estrone
Wehgen
Α,β-hydroxypropionate
Α,β-hydroxypropionic acid
Î’-aminoethanol
Î’-aminoethyl alcohol
Î’-ethanolamine
Î’-hydroxyethylamine
|
|
6 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
7 |
|
Neuroprotective Agents |
|
Phase 3 |
|
|
|
8 |
|
Excitatory Amino Acid Antagonists |
|
Phase 3 |
|
|
|
9 |
|
Anticonvulsants |
|
Phase 3 |
|
|
|
10 |
|
Protective Agents |
|
Phase 3 |
|
|
|
11 |
|
Psychotropic Drugs |
|
Phase 2, Phase 3 |
|
|
|
12 |
|
Antidepressive Agents |
|
Phase 2, Phase 3 |
|
|
|
13 |
|
Hormones |
|
Phase 3 |
|
|
|
14 |
|
Thyrotropin-Releasing Hormone |
|
Phase 3 |
|
|
|
15 |
|
Varenicline |
Approved, Investigational |
Phase 2 |
|
249296-44-4 |
5310966 |
Synonyms:
6,7,8,9-Tetrahydro-6,10-methano-6H-pyrazino(2,3-H)benzazepine
7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-H)(3)benzazepine
Champix
Champix®|Chantix®|compound 9a [PMID: 16171993]|CP 526555
Chantix
CP-526,555
|
CP-526555
Tartrate, varenicline
Vareniclina
VARENICLINE
Varenicline tartrate
Vareniclinum
|
|
16 |
|
Menthol |
Approved, Experimental |
Phase 2 |
|
1490-04-6, 2216-51-5, 15356-60-2 |
1254 16666 165675 |
Synonyms:
(−)-(1R,3R,4S)-menthol
(-)-(1R,3R,4S)-Menthol
(−)-menthol
(-)-Menthol
(-)-Menthyl alcohol
(-)-trans-p-Menthan-cis-ol
(+)-(1S,2R,5S)-menthol
(+)-(1S,3S,4R)-menthol
(+-)-Menthol
(1a,2b,5a)-5-Methyl-2(1-methylethyl)cyclohexanol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1R-(1-a,2-b,5-a))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1R-(1-Α,2-β,5-α))-5-methyl-2-(1-methylethyl)cyclohexanol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-Menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(−)-menthol
(1R,3R,4S)-(-)-Menthol
(1S,2R,5S)-(+)-menthol
(1S,2R,5S)-menthol
(1Α,2β,5α)-5-methyl-2(1-methylethyl)cyclohexanol
(R)-(-)-Menthol
1-Menthol
1-Methyl-4-isopropyl-3-hydroxycyclohexane
2-Isopropyl-5-methylcyclohexanol
3-Hydroxy-P-menthane
3-P-Menthanol
3-P-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-propan-2-ylcyclohexan-1-ol
AQUA-COOL
AQUASOOTHE
ARJUN
CATARRH
|
D-(-)-Menthol
DERMACOOL
DL-menthol
D-menthol
FEMA NO. 2665
Fisherman's friend lozenges
HALLS
Hexahydrothymol
KARVOL
Kerasal
L-(-)-Menthol
Levomenthol
Lévomenthol
Levomentholum
Levomentol
L-Menthol
l-menthol|levomenthol
LOCKETS
MEGGEZONES
Menthacamphor
Menthol
Menthol natural
Menthol racemic
Menthol racemique
Menthol, (1alpha,2beta,5alpha)-isomer
Menthomenthol
Mentol
MUIRS
Peppermint camphor
p-Menthan-3-ol
Racementhol
Racementholum
Racementol
THERAPEUTIC MINERAL ICE
TIXYLIX DECONGESTANT INH
U.S.p. menthol
VOCALZONE
|
|
17 |
|
Nicotinic Agonists |
|
Phase 2 |
|
|
|
18 |
|
Cholinergic Agents |
|
Phase 2 |
|
|
|
19 |
|
Immunoglobulins, Intravenous |
|
Phase 2 |
|
|
|
20 |
|
Immunoglobulins |
|
Phase 2 |
|
|
|
21 |
|
Antibodies |
|
Phase 2 |
|
|
|
22 |
|
gamma-Globulins |
|
Phase 2 |
|
|
|
23 |
|
Rho(D) Immune Globulin |
|
Phase 2 |
|
|
|
24 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
25 |
|
Ubidecarenone |
Approved, Investigational, Nutraceutical |
Phase 1 |
|
303-98-0 |
5281915 |
Synonyms:
(all-e)-2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione
(all-e)-2,3-Dimethoxy-5-methyl-6-(3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaenyl)-2,5-cyclohexadiene-1,4-dione
2-((all-e)-3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
2,3-Dimethoxy-5-methyl-6-decaprenylbenzoquinone
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methyl- 2,5-cyclohexadiene-1,4-dione
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl]-5,6-dimethoxy-3-methyl-1,4-benzoquinone
4-Ethyl-5-fluoropyrimidine
Adelir
all-trans-Ubiquinone
API 31510
API-31510
Aqua Q 10l10
Aqua Q10
Bio-quinon
Bio-quinone Q10
Coenzyme Q10
Coenzyme Q-10
CO-Enzyme Q10
CoQ
CoQ 10
CoQ10
Ensorb
Kaneka Q10
|
Kudesan
Li-Q-sorb
Liquid-Q
Neuquinon
Neuquinone
NSC-140665
NSC-140865
PureSorb Q 40
Q
Q 10AA
Q 199
Q10
Q-Gel
Q-Gel 100
Q-Ter
Ubidecarenone
UBIDECARENONE FOR SYSTEM SUITABILITY
Ubiquinone
Ubiquinone 10
Ubiquinone 50
Ubiquinone Q10
UBIQUINONE-10
Unbiquinone
Unispheres Q 10
|
|
26 |
|
Pharmaceutical Solutions |
|
Phase 1 |
|
|
|
27 |
|
Vitamins |
|
Phase 1 |
|
|
|
28 |
|
Trace Elements |
|
Phase 1 |
|
|
|
29 |
|
Ubiquinone |
|
Phase 1 |
|
|
|
30 |
|
Micronutrients |
|
Phase 1 |
|
|
|
31 |
|
Dopamine |
Approved |
|
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
32 |
|
Benzocaine |
Approved, Investigational |
|
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
33 |
|
Tannic acid |
Approved |
|
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
34 |
|
Dalfampridine |
Approved |
|
|
504-24-5 |
1727 |
Synonyms:
4-AMINOPYRIDINE
4-aminopyridine|4-AP|Ampyra®|EL-970
4-AP
4-PYRIDINAMINE
4-PYRIDYLAMINE
AMPYRA
AMPYRA EXTENDED RELEASE
AVITROL
DALFAMPRIDINE
EL-970
FAMPRIDINA
|
FAMPRIDINE
FAMPRIDINE-SR
FAMPRIDINUM
FAMPYRA
GAMMA-AMINOPYRIDINE
N07XX07
NEURELAN
NSC-15041
P-AMINOPYRIDINE
γ-Aminopyridine
|
|
35 |
|
Triamcinolone |
Approved, Vet_approved |
|
|
124-94-7 |
31307 |
Synonyms:
11b,16a,17a,21-Tetrahydroxy-9a-fluoro-1,4-pregnadiene-3,20-dione
11beta,16alpha,17alpha,21-Tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dione
11Β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
9a-Fluoro-11b,16a,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9a-Fluoro-11b,16a,17a,21-tetrahydroxypregna-1,4-diene-3,20-dione
9a-Fluoro-16a-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9-Fluoro-11b,16a,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9Α-fluoro-16α-hydroxyprednisolone
Adcortyl
Aristocort
ARISTOCORT A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
Celeste
Cinolone
Cinolone-T
DELPHICORT
Fluoxiprednisolone
fluoxiprednisolone|Kenalog®|Nasacort®
Fluoxyprednisolone
Flutex
Fougera
Kenacort
Kenacort-A
Kenacort-Ag
KENALOG
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
Ledercort
|
NASACORT
Nasacort Aq
Nasacort Hfa
NSC-13397
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Rodinolone
Sk-Triamcinolone
TIAMCINOLONUM
Tiamcinolonum [INN-Latin]
Triacet
Triacort
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
TRIAMCINOLONE
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triam-Tablinen
Triatex
Tricortale
Triderm
Trilone
Tri-Nasal
Tristoject
Trymex
Vetalog
Volon
Volon A
|
|
36 |
|
Dopamine agonists |
|
|
|
|
|
37 |
|
Omega 3 Fatty Acid |
|
|
|
|
|
38 |
|
Potassium Channel Blockers |
|
|
|
|
|
39 |
|
Triamcinolone hexacetonide |
|
|
|
|
|
Synonyms:
ARISTOSPAN
CL-34433
LEDERSPAN
|
TATBA
TRIAMCINOLONE HEXACETONIDE
|
|
40 |
|
Triamcinolone diacetate |
|
|
|
|
|
Synonyms:
ARISTOCORT
KENACORT
ORION
POLCORTOLON
|
TEDAROL
TRIAMCINOLONE 16,21-DIACETATE
TRIAMCINOLONE DIACETATE
|
|
41 |
|
Triamcinolone Acetonide |
|
|
|
|
6436 |
Synonyms:
ADCORTYL
ADCORTYL IN ORABASE
ALLERNAZE
ARISTOCORT
ARISTOCORT A
ARISTOGEL
AUDICORT
AUREOCORT
AZMACORT
FLUTEX
GPPE EAR DPS CAP
GPPE EAR OINT
KENACORT
KENACOURT
KENALOG
KENALOG IN ORABASE
KENALOG-10
KENALOG-40
KENALOG-80
KENALOG-H
NASACORT
NASACORT ALLERGY 24 HOUR
NASACORT AQ
|
NASACORT HFA
NSC-21916
NYSTADERMAL
ORACORT
ORALONE
PEVARYL T.C.
REMIDERM
REMOTIC
SILDERM
TRIACET
TRIACORT
TRI-ADCORTYL
TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE IN ABSORBASE
TRIATEX
TRIDERM
TRIESENCE
TRI-NASAL
TRIVARIS
TRYMEX
VETALOG
ZILRETTA
Zilretta®
|
|
Interventional clinical trials:
(show top 50)
(show all 84)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IV Clinical Trial to Evaluate and Compare the Safety and Efficacy of C-Trelin OD Tab 5mg(Taltirelin Hydrate) in Patients With Ataxia Induced by Spinocerebellar Degeneration |
Unknown status |
NCT04107740 |
Phase 4 |
C-Trelin OD Tab(5mg Taltirelin Hydrate);Placebo |
2 |
Riluzole in Patients With Spinocerebellar Ataxia Type 7: a Randomized , Double-blind, Placebo-controlled Pilot Trial With a Lead in Phase |
Unknown status |
NCT03660917 |
Phase 2, Phase 3 |
Riluzole;Placebo |
3 |
Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 |
Completed |
NCT03347344 |
Phase 3 |
Riluzole;Placebo |
4 |
Randomized Clinical Trial to Assess the Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3 |
Completed |
NCT01096082 |
Phase 2, Phase 3 |
Lithium Carbonate;Placebo |
5 |
A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) |
Completed |
NCT01970124 |
Phase 3 |
KPS-0373, High dose;KPS-0373, Low dose |
6 |
An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) |
Completed |
NCT01970111 |
Phase 3 |
KPS-0373, High dose;KPS-0373, Low dose |
7 |
A Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) |
Completed |
NCT01970098 |
Phase 3 |
KPS-0373, High dose;KPS-0373, Low dose;Placebo |
8 |
A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) |
Completed |
NCT01970137 |
Phase 3 |
KPS-0373, High dose;KPS-0373, Low dose |
9 |
An Additional Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) |
Completed |
NCT02889302 |
Phase 3 |
KPS-0373;Placebo |
10 |
A Double-blind, Randomized, Placebo Controlled, Trial to Assess Safety and Efficacy of SLS-005 (Trehalose Injection, 90.5 mg/mL for Intravenous Infusion) for the Treatment of Adults With Spinocerebellar Ataxia |
Recruiting |
NCT05490563 |
Phase 2, Phase 3 |
SLS-005;Placebo |
11 |
A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects With Spinocerebellar Ataxia. |
Active, not recruiting |
NCT03701399 |
Phase 3 |
troriluzole;Placebos |
12 |
A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects With Spinocerebellar Ataxia |
Active, not recruiting |
NCT02960893 |
Phase 2, Phase 3 |
Troriluzole;Placebo |
13 |
An Open Pilot Trial of BHV-4157 in Adult Subjects With Cerebellar Ataxia |
Active, not recruiting |
NCT03408080 |
Phase 3 |
BHV-4157 |
14 |
The Influence of Deep Repetitive Transcranial Magnetic Stimulation (TMS) on Cerebellar Signs in Patients With Spinocerebellar Ataxia Type 3 (SCA3 - Machado Joseph Disease) |
Completed |
NCT02039206 |
Phase 2 |
|
15 |
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study to Evaluate the Safety and Efficacy of Stemchymal® Infusion for the Treatment of Polyglutamine Spinocerebellar Ataxia |
Completed |
NCT02540655 |
Phase 2 |
|
16 |
Randomized, Placebo-controlled Trial to Test Safety, Tolerability and Efficacy of Lithium Carbonate in Spinocerebellar Ataxia 2 |
Completed |
NCT00998634 |
Phase 2 |
LITHIUM CARBONATE |
17 |
A Pilot, Randomized, Double-blind, Placebo-controlled Phase I Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3 |
Completed |
NCT00992771 |
Phase 2 |
varenicline;placebo |
18 |
Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia |
Completed |
NCT01350440 |
Phase 2 |
|
19 |
A Single-Center, Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study, to Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta® in Patients With Machado-Joseph Disease |
Completed |
NCT02147886 |
Phase 2 |
Cabaletta for IV infusion once weekly during 24 weeks |
20 |
An Open-label, Phase II Study of KPS-0373 in Patients With SCD |
Completed |
NCT00863538 |
Phase 2 |
KPS-0373 |
21 |
A Double-blind, Placebo-controlled, Crossover Study, Followed by Open-label Study of KPS-0373 in Patients With SCD |
Completed |
NCT01004016 |
Phase 2 |
KPS-0373;Placebo |
22 |
The Efficacy of High-Dose Intravenous Immunoglobulin Therapy In Patients With Cerebellar Degeneration: A Double Blind, Placebo Controlled Trial |
Completed |
NCT00034242 |
Phase 2 |
high-dose intravenous immunoglobulin (IVIG) |
23 |
Chinese Medicine WT for Elevating IGF-1 of Patients With Spinocerebellar Ataxia Type 3 - Pilot Study |
Recruiting |
NCT05038306 |
Phase 2 |
Chinese medicine WT |
24 |
A Clinical Research on the Safety/Efficacy of Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Spinocerebellar Ataxia |
Not yet recruiting |
NCT03378414 |
Phase 2 |
|
25 |
Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of CAD-1883 in Adults With Spinocerebellar Ataxia (Synchrony-1) |
Withdrawn |
NCT04301284 |
Phase 2 |
CAD-1883;Placebos |
26 |
Phenylbutyrate in SCA3: a Double-blind, Placebo-controlled Study to Determine Safety and Efficacy of Sodium Phenylbutyrate in Patients With SCA3 |
Withdrawn |
NCT01096095 |
Phase 2 |
Placebo;Sodium Phenylbutyrate |
27 |
An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias |
Unknown status |
NCT02287064 |
Phase 1 |
Intravenous Immune Globulin (IVIG) |
28 |
Pilot Study of Tolerability of Lithium Therapy in Patients With Spinocerebellar Ataxia Type I (SCA1) |
Completed |
NCT00683943 |
Phase 1 |
Lithium Carbonate |
29 |
Safety and Tolerability of Coenzyme Q10 in Adult-Onset Sporadic Spinocerebellar Ataxia |
Completed |
NCT00957216 |
Phase 1 |
Placebo (sugar pill);Coenzyme Q10 |
30 |
A Phase 1, Blinded, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of BIIB132 Administered Intrathecally to Adults With Spinocerebellar Ataxia 3 |
Recruiting |
NCT05160558 |
Phase 1 |
BIIB132;BIIB132-Matching Placebo |
31 |
Natural History of Oculomotor Neurophysiology in Ataxic and Pre-ataxic Carriers of Machado-Joseph Disease/Spinocerebellar Ataxia Type 3 (SCA3/MJD) |
Unknown status |
NCT04229823 |
|
|
32 |
Biomarkers and Genetic Modifiers in a Study of Pre-ataxic and Ataxic SCA3/MJD Carriers (BIGPRO Study) - Astrocytes |
Unknown status |
NCT04419974 |
|
|
33 |
Slowing Down Disease Progression in Premanifest SCA: a Piloting Interventional Exergame Trial |
Unknown status |
NCT02867969 |
|
|
34 |
Machado-Joseph Disease in Israel: Clinical Phenotype and Genotype of a Jew Yemenite Subpopulation |
Unknown status |
NCT02175290 |
|
|
35 |
Identification of Biomarkers in Patients With Autosomal Dominant Cerebellar Ataxia |
Completed |
NCT01470729 |
|
|
36 |
Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxias: a Randomized, Double-blind, Sham-controlled Trial Followed by an Open-label Phase |
Completed |
NCT04153110 |
|
|
37 |
Rehabilitative Trial With Cerebello-Spinal tDCS for the Treatment of Neurodegenerative Ataxia |
Completed |
NCT03120013 |
|
|
38 |
Characterization of the Parkinsonism and Other Non-ataxia Spectrum and Striatal Dopaminergic Degeneration in Spinocerebellar Ataxia Type 6 |
Completed |
NCT01934998 |
|
|
39 |
Neuromuscular Electrical Stimulation on Median Nerve Facilitates Low Motor Cortex Excitability in Human With Spinocerebellar Ataxia |
Completed |
NCT02103075 |
|
|
40 |
Integrative Medicine and Tai-chi in Clinical Status of Spinocerebellar Ataxia |
Completed |
NCT03687190 |
|
conventional medicine |
41 |
Translating Molecular Pathology Into a Therapeutic Strategy in SCA38, a Newly Identified Form of Spinocerebellar Ataxia |
Completed |
NCT03109626 |
|
|
42 |
Clinical Effects of Oral Trehalose In Patients With Spinocerebellar Ataxia 3: A Pilot Study |
Completed |
NCT04426149 |
|
|
43 |
Pathogenic Mechanism of Spinocerebellar Ataxia Type 10 (SCA10) |
Completed |
NCT00004306 |
|
|
44 |
Prospective Study of Individuals at Risk for Spinocerebellar Ataxia Type 1, Type 2, Type 3, Type 6 and Type 7 (SCA1, SCA2, SCA3, SCA6, SCA7) |
Completed |
NCT01037777 |
|
|
45 |
A Prospective, Randomized, Controlled Trial for the Efficacy of Repetitive Transcranial Magnetic Stimulation in Spinocerebellar Ataxia Type 3 |
Completed |
NCT05502432 |
|
|
46 |
The Effect of Whole Body Vibration Training on Neuromuscular Property in Individuals With Ataxia |
Completed |
NCT01983631 |
|
|
47 |
Transcranial Magnetic Stimulation (TMS) in Spino-Cerebellar Ataxia |
Completed |
NCT01975909 |
|
|
48 |
Utility Of Home Based Gait Monitoring, Performance Scores And Functional Visual Assessment In Spinocerebellar Ataxias (SCA) |
Completed |
NCT00654251 |
|
|
49 |
Dysmetria in Motor Function in SCA: Mechanisms and Rehabilitation |
Completed |
NCT02488031 |
|
|
50 |
Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND) |
Completed |
NCT02179333 |
|
|
|